Biologic pathways, biosimilarity, interchangeability, and advanced therapy concepts
9 terms
A comparative analytical assessment showing a proposed biosimilar is highly similar to the reference product across critical quality attributes.
EU category including gene therapy medicinal products, somatic cell therapy medicinal products, and tissue engineered products, regulated under specific EU legislation.
A biological product shown to be highly similar to an FDA-licensed reference product, notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences in safety, purity, and potency.
An FDA center responsible for regulating biological products such as vaccines, blood products, and many cell/gene therapies.